biostudies-literatureUnknown56(9)Russo DThe Transplant Centers belonging to Gruppo Italiano per il Trapianto di Midollo Osseo (GITMO) conducted a survey with the aim of evaluating the effect of SARS-CoV2 pandemic on the allogeneic transplant activity in Italy. The pandemic period from 1/3/2020 to 31/7/2020 was compared with the same period in 2019. Overall, in 2020 there was a 2.4% reduction in the number of allo-HCT cases compared to 2019. Interestingly, this deflection did not affect the acute leukemia cases (+5.7% in 2020). The use of peripheral blood-derived stem cells (+10.7%) and cryopreservation (97.4% of the centers) was highly adopted in 2020. Despite the sanitary emergency, almost all of the surveyed centers declared no impact of SARS-CoV2 pandemic on the transplant timing and outcomes, and the sanitary policy was posiBone marrow transplantation2272-2275https://www.ebi.ac.uk/biostudies/studies/S-EPMC8054130biostudies-literatureChanges in Stem Cell Transplant activity and procedures during SARS-CoV2 pandemic in Italy: an Italian Bone Marrow Transplant Group (GITMO) nationwide analysis (TransCOVID-19 Survey).PMC8054130Russo DFaraci MNarni FZallio FVacca AProia ALeoni AGITMO CentersCiceri FPrete AOldani ECarella AMDellacasa CMOnida FSica SFarina MPiemontese SCaravelli DFederico VPelosini MRonconi SCavattoni IMIori APMirabile MMartino MMaffeis MStorti GNozzoli CMordini NPicardi AElice FCarluccio PGuiducci BMarcatti MFerrario ASecondino SFagioli FBonifazi FCalore ESkert CDe Simone GMichieli MBernardi SMalagola MFalcioni STringali SPolverelli NZecca MOlivieri ASacchi NBalduzzi AZuffa ERabusin MPastore DFacchini LDe Gobbi MImola MMammoliti SGrassi AArmiento DfalseChanges in Stem Cell Transplant activity and procedures during SARS-CoV2 pandemic in Italy: an Italian Bone Marrow Transplant Group (GITMO) nationwide analysis (TransCOVID-19 Survey).The Transplant Centers belonging to Gruppo Italiano per il Trapianto di Midollo Osseo (GITMO) conducted a survey with the aim of evaluating the effect of SARS-CoV2 pandemic on the allogeneic transplant activity in Italy. The pandemic period from 1/3/2020 to 31/7/2020 was compared with the same period in 2019. Overall, in 2020 there was a 2.4% reduction in the number of allo-HCT cases compared to 2019. Interestingly, this deflection did not affect the acute leukemia cases (+5.7% in 2020). The use of peripheral blood-derived stem cells (+10.7%) and cryopreservation (97.4% of the centers) was highly adopted in 2020. Despite the sanitary emergency, almost all of the surveyed centers declared no impact of SARS-CoV2 pandemic on the transplant timing and outcomes, and the sanitary policy was posi2021-01-01T00:00:00Z2021 Sep2025-04-18T21:39:27.376Z2022-02-09T15:50:45.694ZS-EPMC80541303387581010.1038/s41409-021-01287-w